secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126190
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo FY2025 net loss $26M, cash $21.6M; mipletamig 86% CBR in AML; CEO transition
--------------------------------------------------------------------------------

- Mipletamig triplet in 28 frontline AML patients: 86% CBR, 79% CR/CRi, no CRS observed.
- Expanded CD3 pipeline with three new candidates including first trispecific assets.
- Established $60M equity line with Yorkville; supports operations potentially into 2029.
- Cash $21.6M at Dec 31, 2025 (up from $8.7M); net loss $26.0M vs $24.1M in 2024.
- CEO Marvin White becomes Executive Chair; Jeff Lamothe named President and CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526126190/0001193125-26-126190-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000119312526126190/apvo-20260326.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126190

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer